Latest Articles from BioDiscovery Latest 3 Articles from BioDiscovery https://biodiscovery.pensoft.net/ Fri, 29 Mar 2024 11:16:21 +0200 Pensoft FeedCreator https://biodiscovery.pensoft.net/i/logo.jpg Latest Articles from BioDiscovery https://biodiscovery.pensoft.net/ Synthesis of a drug discovery library for the identification of sigma receptors modulators https://biodiscovery.pensoft.net/article/14958/ BioDiscovery 20: e14958

DOI: 10.3897/biodiscovery.20.e14958

Authors: Giacomo Rossino, Marta Rui, Marcello Di Giacomo, Daniela Rossi, Simona Collina

Abstract:

HTML

XML

PDF

]]>
Conference Abstract Mon, 17 Jul 2017 13:24:10 +0300
Sigma 1 receptor modulators as a new weapon against multiple sclerosis https://biodiscovery.pensoft.net/article/14565/ BioDiscovery 20: e14565

DOI: 10.3897/biodiscovery.20.e14565

Authors: Simona Collina, Marta Rui, Giacomo Rossino, Serena Della Volpe, Daniela Rossi, Arianna Scuteri, Alessio Malacrida, Guido Cavaletti

Abstract:

HTML

XML

PDF

]]>
Conference Abstract Wed, 5 Jul 2017 03:40:56 +0300
Drug resistance of cancer cells is crucially affected by expression levels of ABC-transporters https://biodiscovery.pensoft.net/article/11211/ BioDiscovery 20: e11211

DOI: 10.3897/biodiscovery.20.e11211

Authors: Petr Mlejnek, Petr Dolezel, Eliska Ruzickova

Abstract: Dasatinib (DAS), a second generation of tyrosine kinase inhibitor (TKI), represents excellent choice for the treatment of chronic myeloid leukemia resistant to imatinib. Unfortunately, recent laboratory studies suggested that antiproliferative effect of DAS might be significantly reduced due to the overexpression of the ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2. However, whether these drug transporters might compromise therapeutic effect of DAS in clinic is unclear. We believe that the drug transporter expression level is a crucial factor that affects the results and its consideration may help to explain the existing controversy. In addition, clinically relevant concentrations of drug must be used. In our study, human leukemia K562 cells with high and low expression levels of ABCB1 or ABCG2 were used. DAS was applied at nanomolar concentrations. We observed that K562 cells expressing high levels of ABCB1 and ABCG2 contained significantly reduced intracellular levels of DAS and these cells exhibited significantly increased resistance to this drug. Importantly, cells with the low expression of ABCB1 or ABCG2 effluxed DAS less efficiently, however, still significantly. Accordingly, the observed resistance was lower but significant. Conclusions: The antiproliferative effects of DAS might be reduced by ABCB1 or ABCG2. However, the actual effect of these ABC transporters on DAS efficiency depends on their expression levels. The lower expression levels of ABC transporters mediate lower resistance. Considering the fact that expression levels of ABCB1 and ABCG2 transporters are usually low in clinical samples, their contribution to the overall resistance to DAS is probably low but significant.

HTML

XML

PDF

]]>
Research Article Wed, 8 Feb 2017 10:52:09 +0200